BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/16/2015 6:04:00 PM | Browse: 1056 | Download: 1030
 |
Received |
|
2014-06-03 09:12 |
|
Peer-Review Started |
|
2014-06-03 20:10 |
|
To Make the First Decision |
|
2014-07-21 14:18 |
|
Return for Revision |
|
2014-07-28 16:11 |
|
Revised |
|
2014-08-29 00:00 |
|
Second Decision |
|
2014-09-30 10:02 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-09-30 10:25 |
|
Articles in Press |
|
2014-09-30 10:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-02-28 16:58 |
|
Publish the Manuscript Online |
|
2015-03-16 18:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Evidence-Based Medicine |
| Article Title |
Prognostic value of 18F-FDG PET/CT in liver transplantation for hepatocarcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Olivier Detry, Laurence Govaerts, Arnaud Deroover, Morgan Vandermeulen, Nicolas Meurisse, Serge Malenga, Noella Bletard, Charles Mbendi, Anne Lamproye, Pierre Honoré, Paul Meunier, Jean Delwaide and Roland Hustinx |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Astellas Belgium |
|
| Académie de Recherche et d’Enseignement Supérieur (ARES) of the Wallonia-Brussels Federation |
to SM and CM |
|
| Corresponding Author |
Dr. Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, Sart Tilman B35, B4000 Liege, Belgium. olivier.detry@transplantation.be |
| Key Words |
Cancer; Hepatoma; Hepatocellular cancer; Liver transplantation |
| Core Tip |
Patients suffering from hepatocarcinoma are selected for liver transplantation (LT) according to the Milan criteria that were established two decades ago. The aggressiveness of the tumor has also a particular importance, but there is still no ideal way of predicting the risk of recurrence according to pretransplant tumor metabolism. This study confirms that FDG positron emission tomography computed tomography with a tumor/liver activity ratios (RSUVmax) cut-off value of 1.15 is a strong prognostic factor for recurrence and death in patients with hepatocellular cancer (HCC) treated by LT. In addition, in this series, none of the patients outside the MILAN criteria with RSUVmax < 1.15 suffered from recurrence in the follow-up. Further prospective studies should test whether this metabolic index should be systematically included in the pretransplant assessment of HCC patients. |
| Publish Date |
2015-03-16 18:04 |
| Citation |
Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P, Meunier P, Delwaide J, Hustinx R. Prognostic value of 18F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 2015; 21(10): 3049-3054 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i10/3049.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i10.3049 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
